REMARKS

Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached page(s) is captioned "**Version With Markings To Show Changes Made**."

Respectfully submitted,

NIXON & VANDERHYE P.C.

By: _____

Arthur R. Crawford
Reg. No. 25,327

ARC:ecb
1100 North Glebe Road, 8th Floor
Arlington, VA 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100

VERSION WITH MARKINGS TO SHOW CHANGES MADE

IN THE SPECIFICATION

Page 1, before the first line, insert as a separate paragraph:

This application is the US national phase of international application PCT/EP00/09708 filed 4 October 2000, which designated the US.

IN THE CLAIMS

11. The composition of ~~either of~~ claims ~~5 or 9~~ wherein the agonist is used to treat endometriosis.

12. The composition of ~~either of~~ claims ~~5 or 9~~ wherein the agonist is used to treat infertility or to improve fertility.

20. The method of ~~either of~~ claims ~~15 or 19~~, wherein the composition is administrated every 12 to 96 hours.

21. The method of ~~either of~~ claims ~~15 or 19~~, wherein composition is administrated twice weekly.

22. Te method of ~~either of~~ claims ~~15 or 19~~, wherein the composition further comprises a tablet.

25. Use accordingly to claim 23 ~~or 24~~ wherein the medicament is formulated to deliver from less than 1 mg to 8 mg of the ß–adrenergic agonist per dose.

26. Use according to ~~any one of~~ claim 23 ~~to 25~~ wherein the ß–adrenergic agonist is terbutaline.

27. Use according to ~~any one of~~ claims 23 ~~to 26~~ wherein the medicament is formulated to deliver from less than 1 mg to 8 mg of the ß–adrenergic agonist per dose.

28. Use according to ~~any one of~~ claims 23 ~~to 27~~ wherein the bioadhesive carrier comprises a cross-linked water-insoluble but water-swellable polycarboxylic acid polymer.

32. Use according to claim 30 ~~or 31~~ wherein the medicament is for administration every 12 to 96 hours.

33. Use according to claim 30 ~~or 31~~ wherein the medicament is for administration twice weekly.

34. Use according to ~~any one of~~ claims 23 ~~to 33~~ wherein the medicament avoids detrimental blood levels of the ß–adrenergic agonist.

35. Use according to ~~any one of~~ claims 23 ~~to 34~~ wherein the medicament is presented in tablet form.